Share on StockTwits
 

Stock analysts at Barclays started coverage on shares of Celladon Corp (NASDAQ:CLDN) in a report issued on Monday, StockRatingsNetwork reports. The firm set an “overweight” rating and a $15.00 price target on the stock. Barclays’ target price suggests a potential upside of 98.15% from the company’s current price.

Shares of Celladon Corp (NASDAQ:CLDN) opened at 7.57 on Monday. Celladon Corp has a 52-week low of $7.00 and a 52-week high of $8.68. The stock’s 50-day moving average is $7.59 and its 200-day moving average is $7.59. The company’s market cap is $133.8 million.

A number of other analysts have also recently weighed in on CLDN. Analysts at Stifel Nicolaus initiated coverage on shares of Celladon Corp in a research note on Monday. They set a “buy” rating and a $16.00 price target on the stock. Analysts at Wedbush initiated coverage on shares of Celladon Corp in a research note on Monday. They set an “outperform” rating and a $17.00 price target on the stock.

Celladon Corporation (NASDAQ:CLDN) is a clinical-stage biotechnology company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.